Castle Biosciences (CSTL) Upgraded to Buy: Here's Why — Positive
CSTL Zacks Investment Research — February 12, 2025Castle Biosciences (CSTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Criteo S.A. (CRTO) is a Great Momentum Stock: Should You Buy? — Positive
CRTO Zacks Investment Research — February 12, 2025Does Criteo S.A. (CRTO) have what it takes to be a top stock pick for momentum investors?
Doximity (DOCS) is a Great Momentum Stock: Should You Buy? — Positive
DOCS Zacks Investment Research — February 12, 2025Does Doximity (DOCS) have what it takes to be a top stock pick for momentum investors? Let's find out.
CompoSecure (CMPO) Upgraded to Buy: Here's What You Should Know — Positive
CMPO Zacks Investment Research — February 12, 2025CompoSecure (CMPO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BRICS banks bleeding gold bars: China and Russia face runaway gold demand — Negative
AAAU BAR DBP DGL GLD GLDM IAU OUNZ SGOL UGL Kitco — February 12, 2025Ernest Hoffman is a Crypto and Market Reporter for Kitco News. He has over 15 years of experience as a writer, editor, broadcaster and producer for media, educational and cultural organizations.
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting — Neutral
INKT GlobeNewsWire — February 12, 2025NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that it has been selected for an oral presentation at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California. The oral presentation will highlight interim data from the company's ongoing Phase 2 study testing AgenT-797 in combination with Agenus' lead therapeutic combination, botensilimab and balstilimab …
Applies for $58 Million with the Department of Defense Office of Strategic Capital Applies for $58 Million with the Department of Defense Office of Strategic Capital
Churchill Downs Incorporated Opens Owensboro Racing & Gaming in Western Kentucky — Neutral
CHDN GlobeNewsWire — February 12, 2025$100 Million Investment Provides World-Class Entertainment While Supporting Purse Funding for Ellis Park $100 Million Investment Provides World-Class Entertainment While Supporting Purse Funding for Ellis Park
ESTC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Elastic N.V. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! — Neutral
ESTC Accesswire — February 12, 2025NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Elastic N.V. ("Elastic" or "the Company") (NYSE:ESTC) and certain of its officers.
Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting — Neutral
AGEN Business Wire — February 12, 2025LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California. An oral presentation will highlight interim data from the ongoing Phase 2 study of botensilimab and balstilimab (BOT/BAL) in combination with MiNK Therapeutics' iNKT cell therapy, AgenT-797,.
Regis Corporation (RGS) Q2 2025 Earnings Call Transcript — Neutral
RGS Seeking Alpha — February 12, 2025Regis Corporation (NASDAQ:RGS ) Q2 2025 Earnings Conference Call February 12, 2025 8:30 AM ET Company Participants Kersten Zupfer - EVP and Chief Financial Officer Matthew Doctor - President and Chief Executive Officer Conference Call Participants Operator Good morning, and thank you for joining the Regis Second Quarter 2025 Earnings Conference Call. I am your host, Kersten Zupfer, Executive Vice President and Chief Financial Officer.
Shareholders that lost money on Neumora Therapeutics, Inc.(NMRA) should contact The Gross Law Firm about pending Class Action - NMRA — Neutral
NMRA GlobeNewsWire — February 12, 2025NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA).
Investors who lost money on Crocs, Inc. (CROX) should contact The Gross Law Firm about pending Class Action - CROX — Neutral
CROX GlobeNewsWire — February 12, 2025NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Crocs, Inc. (NASDAQ: CROX).
Investors in Novo Nordisk A/S Should Contact The Gross Law Firm Before March 25, 2025 to Discuss Your Rights – NVO — Neutral
NVO GlobeNewsWire — February 12, 2025NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
ESSA Pharma Inc. Class Action: The Gross Law Firm Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 – EPIX — Neutral
EPIX GlobeNewsWire — February 12, 2025NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX).
TD to Exit Remaining Stake in Schwab Amid Strategic Review — Positive
SCHW TD Zacks Investment Research — February 12, 2025The Toronto-Dominion Bank agrees to sell its 10.1% stake in Schwab to pursue strategic review plans. The deal is expected to be accretive to the bank's earnings.
Wabtec Shares Decline on Q4 Revenues & Earnings Miss, Dull View — Neutral
WAB Zacks Investment Research — February 12, 2025WAB's Transit unit performs well in fourth-quarter 2024, with sales increasing 7.1% year over year.
Is the Options Market Predicting a Spike in TransAlta (TAC) Stock? — Neutral
TAC Zacks Investment Research — February 12, 2025Investors need to pay close attention to TransAlta (TAC) stock based on the movements in the options market lately.
Exelon's Q4 Earnings & Revenues Surpass Estimates, Capex Plan Up — Positive
EXC Zacks Investment Research — February 12, 2025EXC's fourth-quarter earnings and revenues are better than expected. It reports an increase in electric delivery volume in the reported quarter.
Martin Marietta's Q4 Earnings Beat, Revenues Miss, Stock Down — Negative
MLM Zacks Investment Research — February 12, 2025MLM's fourth-quarter results reflect higher aggregates shipments and strong pricing actions.
